We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. NEW ORLEANS — A novel “counterintuitive” intervention ...

The researchers demonstrated that glucokinase activation was effective in lowering blood glucose in mice with high-fat diet-induced obesity, while it potentially raised the risk of increasing hepatic ...

Diabetes. 2006;55(1):1-12. Glucokinase is required for GSIR in the physiological range of 4-8 mmol/l. Glucokinase is needed for amino acid and fatty acid stimulation of insulin release. Glucokinase ...

Obesity is a major risk factor for metabolic disorders including non-alcoholic fatty liver disease and type 2 diabetes. It has been reported that non-alcoholic fatty liver disease doubles the ...

vTv Therapeutics announced positive topline results from the Phase 2b AGATA study of the glucokinase activator, TTP399, for the treatment of Type 2 diabetes. vTv Therapeutics announced positive ...

Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a wide range of clinical features, from completely asymptomatic infections to fatal or life-threatening disease.

BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (Nasdaq: ARRY) today announced the presentation of preclinical data on a novel small molecule glucokinase activator (GKA), ARRY-403, a drug for ...

We review the role of a new class of agents in improving glycemic control and reducing diabetes-related vascular disease. TTP399 is an investigational oral, hepatoselective glucokinase activator. The ...

SHANGHAI, CHINA, Oct 10, 2022 - (ACN Newswire) - - Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, ...

TransTech and DiaKine obtain licenses from Novo Nordisk and University of Virginia, respectively. TransTech Pharma obtained worldwide, exclusive licenses from Novo Nordisk. to its clinical glucokinase ...